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1. Introduction 
William S. Tillett (1930) discovered that C-Reactive Protein (CRP) is an acute-phase serum 
protein that reacts with the C polysaccharide of Pneumococcal cell wall. CRP is present in 
human serum and its level increases during systemic inflammation. Therefore, CRP 
represents a sensitive marker of systemic inflammation and tissue damage; precise 
determination of CRP levels has proven to be useful in the screening of various diseases, 
monitoring treatment response, and detection of concomitant infections1).  
In recent years, studies have indicated that arteriosclerosis may be due to vascular 
inflammation, and that CRP concentration in the blood correlates with the degree of 
functional disorder of the vascular endothelium. High CRP serum levels have been shown 
to be a risk factor for anginal damage or myocardial infarction-induced stroke2-4). Therefore, 
a highly sensitive and accurate method of measuring CRP is clinically significant. 
We conducted a sensitive quantification of CRP concentration using latex turbidimetric 
immunoassay (LTIA). This method measures turbidity changes in the latex 
immunoagglutination reaction using a latex reagent containing an antibody or antigen 
conjugated to latex particles5-8). LTIA is a simpler, more rapid, and more highly sensitive 
assay of CRP compared with radioimmunoassay (RIA) and enzyme immunoassay (EIA). 
LTIA can measure CRP concentrations at levels between 10-10–10-11 mol/l of serum, and can 
be performed using automated systems for high throughput immunoassay analysis. 
In this study, we investigated a latex reagent containing an amino acid spacer to measure high-
sensitivity CRP. We measured serum CRP levels in healthy individuals, people with liver 
disease, and diabetics. We report that this method is highly useful and clinically beneficial. 
2. Materials and methods 
2.1 CRP antigens 
We used two kinds of whole CRP and five forms of CRP fragments. The first C-Reactive 
Protein High Control (human serum), termed Human CRP, was purchased from Dako 
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(Glostrup, Denmark) for use as an immunogen and standard. The second whole CRP 
protein, termed recombinant CRP (rCRP), was purchased from Oriental Yeast (Tokyo, 
Japan). This was used in the screening of hybridoma cells for the production of monoclonal 
antibodies. Five CRP fragments were prepared by the production of recombinant CRP 
fragments a method described below for epitope analysis. 
2.2 Production of monoclonal antibodies (MoAbs) 
Two 6 to 8-week-old BALB/c female mice (Oriental Yeast) were immunized biweekly with 
Human CRP. The CRP was injected in complete Freund’s adjuvant (Sigma-Aldrich, St.Louis, 
MO) or incomplete Freund’s adjuvant (Sigma-Aldrich) and sterile saline subcutaneously at 
multiple sites on the ventral area of the mouse. One week following the fifth booster 
immunization, tail blood was collected, and the ability of the antibody present in the serum 
to bind rCRP was determined by ELISA. Splenocytes were prepared 3 d after final 
immunization, and were used in cell fusion experiments. 
The cell fusion experiments were described previously.9) Briefly, immune spleen cells and a 
1:5 ratio of P3U1 myeloma cells cultured in RPMI 1640 medium (Invitrogen, Carlsbad, CA) 
supplemented with 10% v/v FetalClone Ⅱ (Thrmo Fisher Scientific, Waltham, MA) were 
fused using 50% w/v polyethylene Glycol 1500 in 75 mM Hepes (pH 8.0; Roche, Basel, 
Switzerland). The fused cells were then suspended in RPMI 1640 medium containing HAT 
Supplement (HAT medium, Invitrogen), and cultured in 96-well plates (10 cells/100 
l/well) under standard 5% CO2 culture conditions at 37°C. After approximately 10 d in 
culture, the hybridoma supernatants were screened by ELISA. Antibody-secreting 
hybridomas were then expanded in HAT medium, cloned by limiting dilution, and cultured 
for a further 10 d. The hybridomas were then subjected to two further rounds of selection by 
ELISA screening and cloning by limiting dilution. Selected hybridomas were cultured in 
RPMI 1640 medium. The resulting supernatants were used in MoAb characterization. 
MoAbs were isotyped using the IsoStrip Mouse Monoclonal Antibody Isotyping kit (Roche). 
Antibodies were also prepared on a large scale, as ascitic fluid, by inoculating the relevant 
hybridoma cells into 10-week-old pristane-treated male BALB/c mice. The MoAbs included 
in the ascitic fluid were purified by ammonium sulfate precipitation at 50% and by protein 
A or protein G chromatography. 
Care and treatment of the experimental animals conformed to the Nihon University 
guidelines for the ethical treatment of laboratory animals. 
2.3 Detection of antibodies in serum and culture medium by enzyme-linked 
immunosorbent assay (ELISA) 
rCRP diluted in 100 mM carbonate buffer (pH 9.6) was added to 96-well plates and 
incubated for 2 h at 25°C. After three washes with phosphate-buffered saline (PBS) 
containing 0.05% v/v Tween 20 (PBS-T), the wells were blocked for 1 h at 25°C with 5.0% 
w/v skim milk (Becton, Dickinson, Franklin Lakes, NJ) in PBS, and washed 3 times with 
PBS-T. The antibody diluted in mouse serum or hybridoma supernatant was appropriately 
diluted in PBS and added to the wells, and this was incubated for 1 h at room temperature. 
PBS in place of the antibody solution served as a negative control. After three washes in 
PBS-T, 100 l of HRP-conjugated goat anti-mouse IgG secondary antibody (diluted 1:4,000 
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in phosphate buffer) was then added to the wells, and this was incubated for 1 h at room 
temperature. The wells were then washed with TBS-T, and peroxidase activity was 
measured colorimetrically using 100 l of substrate solution containing 0.4% o-
phenylenediamine dihydrochloride (Sigma-Aldrich) in a solution of 0.1% citric buffer (pH 
5.0), and H2O2 added at a final concentration of 0.015% immediately prior to use. Following 
incubation for 20 min at room temperature, the reaction was stopped by the addition of 2N 
H2SO4, and the absorbance at 492 nm was determined using a microplate reader (Spectra 
Max M2, Molecular Devices, Ontario, Canada). 
2.4 Production of recombinant CRP fragments 
2.4.1 Amplification of the CRP gene 
Genomic DNA was extracted from whole blood using the GFX Genomic Blood DNA 
Purification kit (GE healthcare, Buckinghamshire, England). Using the extracted genomic 
DNA as template, seven forward primers containing the CACC sequence and one reverse 
primer (Table 1) were used to amplify five different CRP gene fragments, named CRP 01, 
CRP 02, CRP 03, CRP 04, CRP 05, CRP a F, CRP a F and CRP b R, CRP b R by polymerase 
chain reaction (PCR). 
 
Primer Sequence (5′3′) Tm (°C ) Length 
(bp) 
CRP-01 5′-CACCATGTCGAGGAAGGCTTTTG-3′ 70.5 612 
CRP-02 5′-CACCTCGTATGCCACCAAGAGACA-3′ 71.1 465 
CRP-03 5′-CACCAGGGTGAGGAAGAGTCTGAAG-3′ 70.1 276 
CRP-04 5′-CACCGAAGGAAGCCAGTCCCT-3′ 76.6 183 
CRP-05 5′-CACCACCATCTATCTTGGCGGG-3′ 71.3 105 
CRP-R 5′-TCAGGGCCACAGCTGGGGTTT-3′ 73.9 - 
CRP-a-F 5′-CACCGACATGTCGAGGAAG-3′ 64.5 300 
CRP-a-R 5′-TCAGGACTCCCAGCTTGTACA-3′ 64.7 - 
CRP-b-F 5′-CACCGGGTACAGTATTTTC-3′ 56.9 375 
CRP-b-R 5′-TCAGTTAATCTCATCTGGTGA-3′ 57.2 - 
Table 1. Forward and Reverse primers for Recombinant CRP 
2.4.2 Expression of recombinant CRP fragments 
Amplified CRP gene fragments were separated by agarose gel electrophoresis containing 0.8 
g/ml of crystal violet. Separated DNA fragments were then extracted and purified using 
WizardSV GEL and PCR Clean-up System (Promega, Madison, WI). 
pET100/D-TOPO vector (Invitrogen) was used to express the CRP fragments. pET100/D-
TOPO vector and purified DNA were mixed, and the mixture incubated for 5 min at room 
temperature to complete ligation. Escherichia coli TOP10 competent Cells (Invitrogen) were 
then added to the mixture on ice, which was incubated for 15 min and transformed by the 
heat-shock treatment method for 30 s at 42°C. Transformed colonies were then identified by 
colony PCR. The recombinant plasmids were purified using the Wizard SV GEL and SV 
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Miniprep DNA Purification Systems (Promega), and were transformed into E. coli BL21 Star 
(DE3) (Invitrogen) by heat-shock treatment for 30 s at 42°C . S.O.C. medium (Super Optimal 
broth with Catabolite repression) containing 2% Tryptone, 0.5% Yeast Extract, 10 mM 
sodium chloride, 2.5 mM potassium chloride, 10 mM magnesium chloride, 10 mM 
magnesium sulfate, and 20 mM glucose was then added, the mixture was incubated for 1 h, 
and the culture solution was transferred to Luria-Bertani broth containing ampicillin (100 
Ǎg/ml) and cultured for a further 20 h at 37°C. When an optical density (O.D, ǌ = 600 nm) of 
0.7 was achieved, isopropyl β-D-1-thiogalactopyranoside (IPTG) was added to a final 
concentration of 1.0 mM. Following 1.5 h incubation, the cells were separated from the 
culture supernatant by centrifugation (5 min at 14,000 × g) and the E. coli pellet was lysed 
with lysis buffer containing 3 mM potassium dihydrogenphosphate, 47 mM dipotassium 
hydrogenphosphate, 0.4 M sodium chloride, 0.1 mM potassium chloride, 10% v/v glycerine, 
0.5% v/v Triton X-100, and 1 mM Imidazole. The suspension was then subjected to three 
rounds of freeze-thawing, and was divided into soluble and insoluble fractions by 
centrifugation (5 min at 14,000 × g). The proteins in each fraction were then analyzed by 
sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE). 
2.5 Epitope analysis by western blotting 
Expressed CRP fragments were separated by SDS-PAGE on a 12.5% acrylamide gel and 
transferred to PVDF membrane (Bio-Rad Laboratories, Hercules, CA) using the iBlot Gel 
Transfer Device and iBlot Transfer stacks mini (Invitrogen) at 20 V for 6 min. A PVDF 
membrane was then submerged in methanol and ultra pure water and sandwiched in the 
iBlot Transfer stack mini system. The membrane was blocked for 1 h at 25°C in 5.0% w/v 
skim milk in PBS-T and washed 3 times in PBS-T. The membranes were then incubated with 
4 MoAbs, numbered 4, 5, 7, and 8, for 1 h at room temperature, followed by alkaline 
phosphatase (AP)-conjugated goat anti-mouse IgG for 1 h at room temperature. Finally, 
protein bands were visualized using a substrate solution prepared by diluting BCIP/NBT 
(Moss, Pasadena, MD) 1:10 in buffer (pH 9.8) containing 50 mM 2-amino-2-hydroxymethyl-
1,3-propanediol, Tris, 50 mM sodium chloride, and 25 mM magnesium chloride 
hexahydrate. 
2.6 Preparation of anti-CRP latex reagents using monoclonal antibodies (MoAbs) 
The binding of antibody to latex particles was performed using the water-soluble 
carbodiimide (WSC) method10) with 1-ethyl-3-(3-dimethyl-aminopropyl) (EDAC; Dojindo 
Laboratories, Kumamoto, Japan). In this method, carbodiimide activation of carboxylate 
groups on the surface of latex particles (under acidic conditions) produces an unstable 
reaction intermediate, O-acylisourea. O-acylisourea subsequently reacts with N-
hydroxysuccinimide (NHS; Acros Organics, Antwerp, Belgium) to produce a stable NHS 
ester (Fig. 1). 
Briefly, 0.1 ml of 10% polystyrene latex particles, 0.225 mm in diameter (G1225; JSR, Tokyo, 
Japan), was added to 1.9 ml of buffer A containing 0.05 mol/l 2-morpholinoethanesulfonic 
acid monohydrate (MES) buffer (pH 5.6). The mixture was then centrifuged at 22,600 × g for 
20 min, and the precipitate was resuspended in 1.0 ml of buffer A. This suspension was then 
added to 2.0 ml of 20 mg/ml EDAC and 0.23 ml of 50 mg/ml NHS, both dissolved in buffer 
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A; the mixture was stirred for 30 min at room temperature to form the NHS ester. After 
production of the NHS ester, the suspension was washed twice with buffer A and the 
precipitate was resuspended in 1.0 ml of buffer A. The suspension was then added to 2.0 ml 
of 0.133 mmol/ml amino acid, and the mixture was stirred for 30 min at 37°C and 
centrifuged at 22,600 × g for 20 min. The precipitate was then washed with buffer A by 
centrifugation. Similarly, anti-C-reactive protein (anti-CRP) antibody (100 Ǎg/ml in 1.0 ml of 
buffer A) (Immuno Probe, Saitama, Japan) was conjugated to the latex particles with an 
amino acid spacer. The latex-conjugated anti-CRP antibody was resuspended in 1.0 ml of 
buffer A, and the suspension was added to 1.0 ml of 1.0% w/v denatured bovine serum 
albumin (dnBSA). The suspension was then stirred for 30 min at 25°C and washed with 
buffer B, containing 0.1 mol/l Tris buffer (pH 8.2) by centrifugation at 22,600 × g for 20 min. 
The precipitate was then suspended in buffer B. 
 
Fig. 1. Conjugation of antibody to Carboxyl Modified (CM) latex by carbodiimide. 
2.7 Reaction conditions and evaluation of latex reagents using monoclonal antibodies 
(MoAbs) and polyclonal antibobies (PoAbs) 
Latex agglutination due to the antibody-antigen reaction was measured by the automated 
latex photometric immunoassay system (LPIA-S500; Mitsubishi Kagaku Iatron, Tokyo, 
Japan).6) To obtain calibration curves for CRP ranging from 0.5 to 200 ng/ml, 30 Ǎl of 
standard CRP solution at various concentrations was diluted with 0.1 M Tris-BSA buffer 
(pH 8.2) containing 0.1 M Tris, 0.1% w/v EDTA2Na, 0.8% w/v sodium chloride, 1% w/v 
BSA, and 0.1% w/v sodium azide following the manufacturer’s directions. Thirty Ǎl of 
sample and 50 Ǎl of 0.1 M Tris-BSA buffer (pH 8.2) were then transferred to a plastic cuvette, 
and 40 Ǎl of 0.25% latex reagent solution and 180 Ǎl of 0.1 M Tris-BSA-PEG buffer (pH 8.2) 
containing 1% w/v PEG20000 were added. The rate of the latex agglutination was 
calculated by recording the absorbance at 800 nm at 12-s intervals, as reported previously.6) 
Latex reagents prepared using the 4 MoAbs were evaluated for sensitivity, linearity, and 
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stability of latex agglutination. Specimens were properly diluted and measured for CRP 
concentration. 
2.8 Anti-CRP polyclonal antibody and the F(ab’)2 fragment  
Anti-CRP polyclonal antibody was produced by Immuno Probe (Saitama, Japan) The 
specific F(ab’)2 fragment was prepared by pepsin digestion, as previously described.11) 
2.9 Clinical samples 
We tested CRP levels in serum samples of 62 healthy individuals, 263 patients with liver 
disease, and 230 diabetic patients. Fifty diabetic patients had type 2 diabetes and were not 
under insulin treatment. All patients were examined in the Surugadai Nihon University 
Hospital, Tokyo, between April 2005 and March 2007. The study was approved in advance 
by the Ethics Committee of the hospital, and was conducted in accordance with the Helsinki 
Declaration. All study participants provided written informed consent prior to participation 
in this study. 
3. Result and discussion 
3.1 Characterization of monoclonal antibodies produced by established hybridomas 
MoAbs produced from hybridoma cells were screened by ELISA, and seven MoAbs were 
subsequently established as stable hybridoma cells. Examination of MoAb reactivity 
revealed that hybridoma clone 5 had the highest sensitivity. Clonal sensitivity was ranked in 
the following order: clone 5 > clone 8 > clone 7 > clone 9 > clone 3 > clone 4 > clone 1. These 
isotypes and subclasses were then analyzed using the IsoStrip kit. The MoAb 1 produced 
from hybridoma clone 1 and clones 3, 5, 7, 8, and 9 were IgG1ǋ, while clone 4 was IgG2aǋ. In 
addition, the specificity of the MoAbs was confirmed by western blotting using Human 
CRP. The MoAbs recognized a protein band at a molecular weight of approximately 11,500 
Da. These results suggest that the MoAbs reacted specifically with CRP. 
3.2 Epitope analysis 
Protein epitopes are generally present in the areas of a protein that exhibit specific 
characteristics, including hydrophilicity,12,13) solvent accessibility,14) mobility,15,16) and the 
presence of protrusions.13) In addition, epitopes are commonly 5–10 amino acid residues 
containing loops and/or protruding regions.17,18) The hydrophilicity plot for the prediction 
of protrusions from the protein sequences can be measured by a simple method.13) 
Hydropathy analysis of CRP in this study was performed by the SOSUI system WWW-
based tool (http://bp.nuap.nagoya-u.ac.jp/sosui/),19) since it was anticipated that 
hydrophilic epitopes would be present in CRP. 
We mapped epitope locations using the seven CRP fragments. CRP-01 was 203 amino acid 
residues in length and was translated from the second exon (amino acid sequence positions 
4 to 206); CRP-02 was 155 amino acid residues in length (amino acid sequence positions 52 
to 206); CRP-03 was 91 amino acid residues in length (amino acid sequence positions 116 to 
206); CRP-04 was 60 amino acid residues in length (amino acid sequence positions 147 to 
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206); CRP-05 was 34 amino acid residues in length (amino acid sequence positions 173 to 
206); CRP-a was 100 amino acid residues in length (amino acid sequence positions 4 to 103). 
and CRP-b was 125 amino acid residues in length (amino acid sequence positions 49 to 173). 
The seven recombinant CRP peptide fragments were then expressed in E. coli and their 
relative molecular weights were observed by SDS-PAGE and Coomassie Brilliant Blue 
staining (Fig. 2). In each case, the relative molecular weight corresponded to the predicted 
size of the recombinant peptide fragments. 
 
(A) 
 
(B) (C) 
(A) Molecular weight marker (lane 1), CRP-01 of recombinant CRP fragment (lane 2), CRP-02 (lane 3), 
CRP-03 (lane 4), CRP-04 (lane 5), and CRP-05 (lane 6) were separated by SDS-PAGE and stained with 
Coomassie Brilliant Blue. Recombinant CRP fragments for CRP-01, CRP-02, CRP-03, CRP-04, and CRP-
05 correspond to molecular weights of 26.3, 19.9, 11,7, 6.8, and 4.0 kDa respectively. (B) Recombinant 
protein CRP-a, Lane 1-5: Add IPTG to culture pellet 0-5h, Lane 6-10: Culture pellet 0-5h. (C) 
Recombinant protein CRP-b, Lane 1-5: Add IPTG to culture pellet 0-5h, Lane 6-10: culture pellet 0-5h. 
M: Low range molecular weight marker (Wako Pure Chemical Industries) 
Fig. 2. SDS-PAGE Analysis of Recombinant CRP Fragments Expressed in E. coli. 
The results of epitope analysis using Western blot are presented in Table 2. MoAbs 4, 7, and 
8 were found to react with all fragments, while MoAb 5 reacted with CRP-01, CRP-02, CRP-
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03, and CRP-04. This suggests that the C-terminal fragment (positions 173 to 206, Fig. 3B) 
contains the epitope for MoAbs 4, 7, and 8 while the fragment containing amino acid 
residues 147 to 172 (Fig. 3A) contains the epitope for MoAb 5. It is not a hydrophilicity 
epitope. However, these epitope regions include helix and loop structures, and there have 
been only a few reports of cross-reaction with these epitopes.20,21) Hence, we hypothesized 
that these epitopes represent specific antigen sites. 
 
Monoclonal 
antibody 
Isotype 
Reactivity with Recombinant CRP 
CRP-
01 
CRP-
02 
CRP-
03 
CRP-
04 
CRP-
05 
CRP-a CRP-b 
No. 4 IgG2aǋ + + + + + + + 
No. 5 IgG1ǋ + + + + – + + 
No. 7 IgG1ǋ + + + + + + + 
No. 8 IgG1ǋ + + + + + + + 
Table 2. Reactivity of the Anti-CRP Monoclonal Antibody with CRP Fragments by Western 
Blot Analysis 
 
The C-terminal fragment from positions 173 to 206 (B) might contain the epitopes for MoAbs 4, 7, and 8, 
while the fragment spanning positions 147 to 172 (A) is thought to contain the epitope for MoAb 5.  
※Cross-reactive site with heat shock protein 60.20)  
※※ Site similar to pentraxins in other species.21) 
Fig. 3. Hydrophobicity Plot of the CRP Amino Acid Sequence. 
3.3 Reactivity of anti-CRP latex reagents using polyclonal antibody (PoAb) 
3.3.1 Optimization of amino acid spacer concentration 
First, bond concentrations of the amino acid spacers were examined. Preparation of latex 
reagent with amino acid spacers was synthesized using glycine at concentrations of 1.0–20 
mg/ml, and the reagent produced binding antibody using latex synthesized at each glycine 
concentration. The examination of reactivity was performed to react CRP antigen with the 
binding antibody using the synthesized reagent. As seen in Fig. 3, the examination of 
reactivity improved as glycine concentrations increased. The optimum glycine concentration 
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was 10 mg/ml, and the excess glycine bond was decreased by the reactivity of latex reagent. 
Thus, latex responsiveness was improved by the combination of the amino acid and latex at 
a concentration of 0.26 mmol. 
The result of each reagent using glycine (Gly), alanine (Ala), valine (Val), leucine (Leu), 
and peptide synthesized by Fmoc solid phase (5 molecule bond of glycine: Gly5) are shown 
in Fig. 4. The rank order of reactivity was Gly5 > Gly > Ala > Leu > Val. Each amino acid 
produced a gentle sloping curve, and Gly5 produced a good reaction curve.  
The accuracy of each amino acid is shown in Table 3. CV was about 0.5 or less and the 
stabilizing reagent was synthesized. Gly sensitivity is shown in Fig. 5. We demonstrated that 
it was possible to measure up to 500 ng/dl by calculating mean ± 3 SD values. 
This study demonstrates that a latex reagent made by using 5 types of amino acid spacer 
molecules increased reactiveness by 40% as compared to using only 1 glycine molecule. It is 
possible that the long amino acid spacer reduces steric hindrance in the antigen-antibody 
reaction with the latex and thus reactiveness to the antibody is increased. Because the 
reactiveness is examined by using the amino acid, the position of the carboxyl group is the 
same as the amino group necessary for the peptide bond formation. Therefore, the length of 
the latex particle and antibody is constant. Because the alkyl group of the amino acid used is 
aliphatic, the hydrophobe of the amino acid, and the volume of the molecule are chiefly 
different (Table 4), the difference in reactiveness may be due to the side chain of the amino 
acid. As seen in Fig. 6, there was a 70% or greater increase in reactivity for all amino acids 
when the bonding amounts of the amino acid were compared, and a significant difference 
was not seen in the amount of antibody binding. Therefore, it is suggested that the 
reactiveness is due to the interaction of the aliphatic amino acid spacer with the 
hydrophobe. 
 
Fig. 4a. Comparison of reactivity in various concentration of glycine spacer 
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Fig. 4b. Comparison of reactivity in various types of amino acid spacers 
 
Glycine 
Concentration 
(Ǎg/dl) 0 1.0 2.0 3.0 4.0 5.0 
Mean (absorbance) 0.058 0.288 0.430 0.481 0.542 0.583 
SD 0.007 0.009 0.022 0.018 0.029 0.015 
CV(%) 12.70 3.22 5.18 3.68 5.40 2.56 
Alanine 
Concentration (Ǎg/dl) 0 1.0 2.0 3.0 4.0 5.0 
Mean (absorbance) 0.021 0.107 0.171 0.224 0.258 0.288 
SD 0.010 0.012 0.021 0.030 0.033 0.041 
CV(%) 49.44 11.24 12.26 13.53 12.92 14.06 
Valine 
Concentration (Ǎg/dl) 0 1.0 2.0 3.0 4.0 5.0 
Mean (absorbance) 0.070 0.268 0.380 0.446 0.380 0.446 
SD 0.006 0.016 0.022 0.026 0.022 0.026 
CV(%) 8.74 5.89 5.85 5.81 5.85 5.81 
Leucine 
Concentration (Ǎg/dl) 0 1.0 2.0 3.0 4.0 5.0 
Mean (absorbance) 0.191 0.389 0.515 0.550 0.604 0.603 
SD 0.029 0.064 0.069 0.078 0.080 0.089 
CV(%) 15.18 16.54 13.33 14.10 13.22 14.81 
Gly5 
 
Concentration (Ǎg/dl) 0 1.0 2.0 3.0 4.0 5.0 
Mean (absorbance) 0.051 0.302 0.505 - - 0.896 
SD 0.05 0.081 0.083 
  
0.093 
CV(%) 15.54 10.95 7.32 
  
7.96 
Table 3. With in-run precision 
㻜
㻞㻜
㻠㻜
㻢㻜
㻤㻜
㻝㻜㻜
㻜㻚㻜 㻝㻚㻜 㻞㻚㻜 㻟㻚㻜 㻠㻚㻜 㻡㻚㻜
㻯RP 㻯㼛㼚㼏㼑㼚㼠㼞㼍㼠㼕㼛㼚 㻔μg㻛㼐㼘㻕
㻳㼘y㻡 㻳㼘y A㼘㼍 L㼑㼡 V㼍㼘
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Fig. 5. Detection sensitivity 
Amino 
acid 
MW pI 
The solubility of 
amino acid in H2O 
Glycine 75.07 5.97 14.18 䠄  0°C䠅 
   24.99 䠄 25°C䠅 
Alanine 89.09 6.00 12.73 䠄  0°C䠅 
   16.51 䠄 25°C䠅 
Valine 117.15 5.96 ー 䠄  0°C䠅 
   8.34 䠄 25°C䠅 
Leucine 131.18 5.98 2.27 䠄  0°C䠅 
   2.19 䠄 25°C䠅 
Table 4. Amino acid spacers 
 
Fig. 6. Amount of conjugated amino acid and antibody 
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3.3.2 Immunoreactivity of prepared latex reagent 
The latex reagent was produced by the method previously described using F(ab′)2 antibody, 
and the reactivity was compared with the conventional reagent. The F(ab′)2 reagent and 
conventional reagent were used to draw calibration curves from standard CRP samples  
and CRP levels derived from the 263 clinical samples from patients with liver disease.  
As seen in Fig. 7, the F(ab′)2 reagent correlated with a conventional reagent (r2 = 0.746,  
y = 0.4879, and x + 1.77). Moreover, when CRP concentration was between 0.030 and 2.0 
mg/dl, the correlation was r2 = 0.829, y = 0.909, and x + 0.6073, indicating that there was a 
significant correlation at low concentrations. However, at high latex concentrations, this 
method was less sensitive.  
 
Fig. 7. Comparative study of CRP latex reagent 
3.3.3 LTIA for titration of the MoAb and oligoclonal antibody 
Three latex reagents with MoAb were used to quantify the CRP antigen by LTIA. The 
immunoreactivity curve of the latex agglutination rates using the various antibodies is 
shown in Fig. 8. We found that the reaction rates increased with the concentration of CRP 
antigen in an approximately linear fashion. The reactivity of these reagents was ranked in 
the following order: MoAb 5 > MoAb 8 > MoAb 7. This order of reactivity observed for the 
latex agglutination tests was found to be the same as that for the ELISA tests. The detection 
limit, which was calculated as the concentration equivalent to 3 standard deviations above 
the mean signal from 10 replicates of the zero standard, was calculated at 10 ng/ml. 
Further, we prepared two types of latex reagent. First we mixed the two above-mentioned 
latex reagents together to form “mixed latex reagents,” and combined these suspensions 
with CRP (Fig. 9). Then  latex reagents were prepared using two MoAbs at a total antibody 
concentration of 100 Ǎg/ml, and the latex reagent with two antibodies as the oligoclonal 
antibody were reacted with the CRP antigen (Fig. 10). The sensitivity of the latex reagents 
containing MoAb 5 was found to be the highest, and the latex reagents with the oligoclonal 
antibody were more sensitive than the mixed latex reagents. The lower limit of CRP antigen  
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The latex reagent containing MoAb 5 (○) was found to have the highest activity, while the latex reagent 
containing MoAb 7 (●) was found to have the lowest activity. The latex reagent containing MoAb 8 (△) 
was found to have an intermediate level of activity. 
Fig. 8. Comparison of Reactivity between Latex Reagents. 
 
Three types of mixed latex reagents were prepared using MoAb 5 latex reagent and MoAb 7 latex 
reagent (○), MoAb 5 latex reagent and MoAb 8 latex reagent (●), and MoAb 7 latex reagent and MoAb 8 
latex reagent (娟). The mixed latex reagents containing MoAb 5 were found to have higher activity than 
the others. 
Fig. 9. Comparison of Latex Reagent Reactivity Following Mixing of Two Types of Latex 
Reagents Containing Different MoAbs. 
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Three types of latex reagents with oligoclonal antibody were prepared with a combination of MoAb 5 
and 7(●), MoAb 5 and 8(娟), and MoAb 7 and 8(○). Two types of latex reagents sensitizing MoAb 5 were 
found to have higher sensitivity than the rest. 
Fig. 10. Comparison of Reactivity Among Latex Reagents Containing Two Kinds of MoAbs. 
detection, which was defined by the mean ± 3 SD method, was calculated as 10 ng/ml for 
the mixed latex reagents and 5 ng/ml for the latex reagent containing the oligoclonal 
antibody. When MoAbs for two different epitopes were used, the resulting latex reagent 
exhibited higher sensitivity than the MoAbs for two nearby epitopes. We suggest that latex 
reagents can be further increased in sensitivity through the use of MoAbs directed against 
remote epitopes. 
3.4 Examination of clinical significances for quantification of CRP level in normal, 
hepatic disease, and diabetic subjects 
The CRP level of sera in normal, hepatic disease, and diabetic subjects were measured by 
latex reagents prepared using glycine spacers (Fig. 11). Normal subjects (n = 62) showed a 
CRP average value of 0.03 mg/dl (maximum, 0.12 mg/dl; minimum, 0.01 mg/dl). These 
CRP levels in sera were 0.02 mg/dl lower than reference healthy individuals . 
Patients with liver disease (n = 263) caused by hepatitis B and C had an average CRP level of 
0.14 mg/dl (maximum, 2.7 mg/dl; minimum, 0.04 mg/dl) in sera. 
Type 2 diabetes mellitus subjects (n = 230) had an average CRP level of 0.07 mg/dl 
(maximum, 1.9 mg/dl; minimum, 0.01 mg/dl). 
Furthermore, CRP level in hepatitis B and C patients sera was compared with hepatic 
disease subjects classified as having hepatitis, hepatic cirrhosis, and hepatic cancer (Fig. 12). 
CRP levels tended to increase with the advancement of the disease. 
This new method of assaying CRP, which uses a latex reagent made with a glycine spacer, 
shows that there is a tendency for CRP levels to increase with age. We were able to get CRP 
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readings at low concentrations (0.020 mg/dl) in a subset of healthy volunteers (n = 63) who 
were between 20–30 years of age. This method was also used to measure CRP levels in patients 
with liver disease, and the levels were correlated with disease advancement. In traditional 
CRP assays, small changes are not usually detected owing to viral infection. Moreover, 
because the liver produces CRP, the decrease of CRP production has been linked to hepatic 
infection. However, the change in such CRP level due to liver disease was confirmed by this 
new highly sensitive CRP density measurement. Our data indicate that CRP is produced by 
the inflammatory response of the liver in patients with hepatitis B and C.  
We also measured CRP levels in patients with diabetes. Chronic high blood sugar in diabetic 
patients increases the risk of arteriosclerosis. Recent studies indicate that insulin-resistant 
diabetes is especially correlated with arteriosclerosis and that heightened level of CRP in 
type 2 diabetes may be a sensitive marker of arteriosclerosis.  
This study indicates that CRP levels are not only elevated in people with particular 
infectious diseases, cardiac infarction, and arteriosclerosis, but also in the sera of people 
with liver disease and diabetes. These findings indicate that assaying CRP level will become 
more important for diagnosing multiple diseases and may be used to measure the 
effectiveness of therapies for patients with liver disease. Additionally, this newly developed 
method can detect even small changes in CRP levels and thus is much more sensitive than 
traditional methods. 
 
Fig. 11. Box and whisker plots in CRP measurement of normal subjects and patients 
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Fig. 12. Box and whisker plots in CRP measurement of various types of hepatic disease 
4. Conclusion  
We developed four novel MoAbs directed against CRP (MoAb 4, 5, 7, and 8), and classified 
these antibodies into two major groups. The epitopes for MoAbs 4, 7, and 8 were located 
between the amino acids residing at positions 173 to 206 of the CRP sequence. The epitope 
for MoAb 5 was located between the amino acids residing at positions 147 to 172 of the CRP 
sequence. These MoAbs were used in the preparation of latex reagents. The latex reagents 
constructed using these MoAbs were found to be highly sensitive. Moreover, the latex 
reagents, containing a cocktail of MoAbs specific for different epitopes, were also found to 
be highly sensitive. The lower limit of detection of CRP antigen, which was defined using 
the mean ± 3 SD method, was calculated to be 5 ng/ml for the latex reagents containing 
oligoclonal antibodies. Furthermore, the latex reagents that were prepared using three kinds 
of MoAbs reacted specifically with CRP-present patients with type-2 diabetes. In Fig. 12, the 
obtained CRP value, appear to be indicated the hepatitis disease situation with the extreme 
increased of CRP values in transition of disease phase from the point of these clinical 
evaluations. We concluded that high sensitive CRP measurement should be usable in the 
diagnosis of metabolic syndrome, such as diabetes and cardiac disease, early prediction of 
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infection disease, and clinical follow-up of infection of neonates that show low 
concentrations of CRP. 
We suggest that latex reagents can be increased in sensitivity and specificity through the use 
of MoAbs directed against remote epitopes. The results from this study might also prove to 
be applicable to additional substances such as interleukin, etc. 
This study presents a new CRP reagent with an amino acid spacer. In this method, the latex 
particles contain a glycine spacer, the anti-CRP antibody can be supported, and the 
orientation can be given to the antibody. As compared with other methods, this method 
allows for quick, efficient, and highly sensitive measurement of CRP levels even in low 
concentrations. 
Additionally, we determined the serum CRP levels in a clinical sample of healthy subjects, 
people with liver disease, and diabetic subjects to be 0.1374 mg/dl, 0.0332 mg/dl, and 0.0704 
mg/dl, respectively. There was a significant difference in the CRP levels between patients 
with type B and type C hepatitis. We also detected small differences in CRP levels between 
type 1 and 2 diabetic patients. 
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